Suggested Topics within your search.
Suggested Topics within your search.
-
2861
In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015–2023)
Published 2025-06-01“…Omadacycline in vitro activity was assessed against 919 bacterial isolates collected from patients with bone/joint infections in the United States and Europe (2015–2023) and 3945 rarely encountered bacterial pathogens from patients (multiple infection sites) in the United States (2015–2023) as part of the SENTRY Antimicrobial Surveillance Program. program. Methods: Broth microdilution susceptibility testing followed Clinical and Laboratory Standards Institute M07 (2024) and M100 (2024) guidelines. …”
Get full text
Article -
2862
-
2863
-
2864
-
2865
-
2866
-
2867
-
2868
-
2869
-
2870
-
2871
-
2872
-
2873
-
2874
-
2875
-
2876
-
2877
-
2878
-
2879
-
2880